Israel vs United Arab Emirates: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Israel
94.0%
in 2024
United Arab Emirates
94.0%
in 2024
Israel rank
34th
United Arab Emirates rank
34th
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Israel
- United Arab Emirates
How they compare
Israel currently reports 94.0% against 94.0% in United Arab Emirates, a difference of 0.0%.
The two have swapped places 2 times across 14 shared years of data; in 2011 it was United Arab Emirates ahead.
Israel ranks 34th and United Arab Emirates ranks 34th of 146 countries.
Across the 2 decades both report, Israel averaged higher in 1 and United Arab Emirates in 1.
Head to head by decade
| Decade | Israel | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 93.8% | 97.8% | 4.0% | United Arab Emirates |
| 2020s | 94.2% | 92.4% | 1.8% | Israel |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Israel or United Arab Emirates?
- Israel, at 94.0% against 94.0% in United Arab Emirates as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Israel and United Arab Emirates?
- 0.0%, with Israel ahead.
- How many years of comparable data are there for Israel and United Arab Emirates?
- 14 years are reported by both, from 2011 to 2024.
- How do Israel and United Arab Emirates rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Israel ranks 34th and United Arab Emirates ranks 34th of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.